GLP1 Europe › Reimbursement checker
Would you qualify for GLP-1 reimbursement?
What this does
Enter your details once and see how they compare with the published public reimbursement criteria in ten European countries at the same time. The same person often qualifies in one country and not in the next.
This checks paperwork rules, not whether a medicine is right for you. It cannot know your medical history, and it is not a prescription pathway.
The criteria in full
The checker above compares your figures with the rules in this table. If you have JavaScript switched off, or you would rather just read them, everything the tool uses is here.
| Country | Reimbursed for obesity? | Criteria as published |
|---|---|---|
| France | Yes, 65% | BMI 40 or above, or BMI 35 or above with at least one weight-related condition. Supervised nutritional management must have failed first, defined as less than 5 percent weight loss over six months. First prescription by a specialist in an obesity centre; renewals by any doctor. A signed form must be shown to the pharmacist each time. |
| United Kingdom | Yes, phased | NICE TA1026, tirzepatide. BMI 35 or above with at least one of: high blood pressure, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease, type 2 diabetes. Threshold reduced by 2.5 for several ethnic groups. Specialist weight management services cover the full eligible population. Primary care is phasing in by cohort: 2026/27 is BMI 35 to 39.9 with four or more conditions. |
| Germany | No, by statute | Section 34 SGB V excludes weight-loss medicines from statutory insurance entirely. No BMI qualifies. Private prescription is legal and available from any doctor at full cost. |
| Netherlands | Not currently | Advised against in July 2024. A reassessment is under way, with a dossier submitted in July 2026 proposing a stepped approach starting at BMI 30 with a weight-related disease, and BMI 35. |
| Estonia | Not currently | Reimbursed for type 2 diabetes only. A cost-benefit study is due in autumn 2026 and reimbursement could begin in spring 2027, likely narrowed to the highest-BMI groups. |
| Sweden | No | TLV refused Wegovy on 23 February 2026. It accepted cost-effectiveness in severe obesity but was not satisfied prescribing could be held within the restriction. |
| Denmark | No | General subsidy refused on 10 July 2025, citing cost against documented benefit and weight regain after stopping. |
| Italy | No | Class C, full patient cost, for weight management. The same molecules are reimbursed for type 2 diabetes under Nota 100. |
| Spain | No | Mounjaro was denied public financing on budget impact grounds. Ozempic is financed for type 2 diabetes only, with prior authorisation. |
| Poland | No | Reimbursed for type 2 diabetes only, with a 30 percent co-payment and strict criteria. A proposal to widen it was rejected in May 2026. |
How to read the result
Meeting the criteria is not the same as getting the medicine. Even in France and the UK, a prescriber still has to agree that treatment is appropriate for you, and in both countries the first prescription has to come through a specific route rather than any doctor.
A "no" almost never means the medicine is unavailable. In every country listed, these medicines can be legally prescribed and dispensed privately. The question this tool answers is only whether the public system pays. Germany is the clearest example: Wegovy sits on pharmacy shelves, it is simply not covered.
Diabetes changes everything. Reimbursement for type 2 diabetes is far more widely available than for obesity, under different rules, in almost every country here. If you have type 2 diabetes, the obesity criteria above are the wrong table to be reading.
These rules move. France's came into force in June 2026 and were already amended once. The Netherlands and Estonia have live reviews. Check the date at the top of this page.
This tool compares numbers against published policy criteria. It is not medical advice, not a diagnosis, and not a prescription pathway, and it cannot account for your medical history, other medications or contraindications. Whether any medicine is suitable for you is a decision for a doctor. If you are worried about your weight or your health, speak to a doctor or a pharmacist.